News: Protagonist Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Read more in our press release: tinyurl.com/r8jwyjde
Read more in our press release: tinyurl.com/r8jwyjde
0:29
Protagonist Therapeutics
Verified account This account is verified. Learn more@ProtagonistTx
Discovering and developing novel therapies through our proprietary peptide technology platform. #biotech #lifesciences #innovation
213 Following 407 Followers 694 Posts
Latest posts 5
Protagonist Therapeutics will participate in four investment bank conferences this November, with members of our senior management team meeting with investors in New York and London.
• 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟭𝟬: Wolfe Research Healthcare Conference
• 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟭𝟮: Truist Securities Biopharma Symposium
• 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟭𝟲: UBS Global Biopharma Conference
• 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟭𝟳: Jefferies Global Healthcare Conference
A replay of the fireside chats will be available on the Investor Relations Events and Presentations webpage following the events.
Learn more: tinyurl.com/2r5hjc8w
#ProtagonistTherapeutics #PTGX #Biotech
• 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟭𝟬: Wolfe Research Healthcare Conference
• 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟭𝟮: Truist Securities Biopharma Symposium
• 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟭𝟲: UBS Global Biopharma Conference
• 𝗡𝗼𝘃𝗲𝗺𝗯𝗲𝗿 𝟭𝟳: Jefferies Global Healthcare Conference
A replay of the fireside chats will be available on the Investor Relations Events and Presentations webpage following the events.
Learn more: tinyurl.com/2r5hjc8w
#ProtagonistTherapeutics #PTGX #Biotech
0:28
Protagonist is very pleased to see another global approval for ICOTYDE™ (icotrokinra)!
ICOTYDE, co-discovered by Protagonist and Johnson & Johnson scientists, has now been approved in the United Kingdom for adults and adolescents with moderate-to-severe plaque psoriasis.
This latest approval builds on approvals in the U.S., China, and EU, bringing ICOTYDE to more patients around the world.
gov.uk/government/new…
#ICOTYDE #PeptideTherapeutics #PTGX
ICOTYDE, co-discovered by Protagonist and Johnson & Johnson scientists, has now been approved in the United Kingdom for adults and adolescents with moderate-to-severe plaque psoriasis.
This latest approval builds on approvals in the U.S., China, and EU, bringing ICOTYDE to more patients around the world.
gov.uk/government/new…
#ICOTYDE #PeptideTherapeutics #PTGX
What a week for Protagonist Therapeutics!
Protagonist received three exciting industry recognitions highlighting our innovation and business performance. With two FDA-approved, first-in-class peptidic medicines, #ICOTYDE™ and #MIMRYLO™ and a growing pipeline of differentiated peptide therapeutics, we continue to build on our successes as we advance new treatment options for patients.
🏆 TIME Best Inventions of 2026: ICOTYDE™ (icotrokinra), jointly discovered by Protagonist and Johnson & Johnson, was named one of TIME's Best Inventions of 2026.
🏆 Newsweek's America's Greatest Mid-Market Companies 2026: Protagonist was recognized for its strong business performance and continued growth.
🏆 Fierce Innovation Awards: Protagonist was named a finalist in the Biotech Innovation category of the 2026 Fierce Innovation Awards. Thank you, Fierce Life Sciences Events, for this recognition!
#PTGX #FierceInnovator #Biotechnology #Innovation #PeptideTherapeutics
Protagonist received three exciting industry recognitions highlighting our innovation and business performance. With two FDA-approved, first-in-class peptidic medicines, #ICOTYDE™ and #MIMRYLO™ and a growing pipeline of differentiated peptide therapeutics, we continue to build on our successes as we advance new treatment options for patients.
🏆 TIME Best Inventions of 2026: ICOTYDE™ (icotrokinra), jointly discovered by Protagonist and Johnson & Johnson, was named one of TIME's Best Inventions of 2026.
🏆 Newsweek's America's Greatest Mid-Market Companies 2026: Protagonist was recognized for its strong business performance and continued growth.
🏆 Fierce Innovation Awards: Protagonist was named a finalist in the Biotech Innovation category of the 2026 Fierce Innovation Awards. Thank you, Fierce Life Sciences Events, for this recognition!
#PTGX #FierceInnovator #Biotechnology #Innovation #PeptideTherapeutics
0:05
We are thrilled to share that ICOTYDE® (icotrokinra) has been named one of TIME Magazine's Best Inventions of 2026 in the Medical & Healthcare category!
Jointly discovered by Protagonist Therapeutics and Johnson & Johnson scientists, ICOTYDE is the first and only targeted oral peptide therapy that selectively blocks the IL-23 receptor, offering a new oral treatment option for patients with moderate-to-severe plaque psoriasis.
This recognition is a testament to the years of dedication, scientific innovation and hard work from the teams at Protagonist and Johnson & Johnson who helped bring ICOTYDE from discovery to patients.
Read more: tinyurl.com/TIMEbestinvent…
#TIMEBestInventions #ICOTYDE #PeptideInnovation
Jointly discovered by Protagonist Therapeutics and Johnson & Johnson scientists, ICOTYDE is the first and only targeted oral peptide therapy that selectively blocks the IL-23 receptor, offering a new oral treatment option for patients with moderate-to-severe plaque psoriasis.
This recognition is a testament to the years of dedication, scientific innovation and hard work from the teams at Protagonist and Johnson & Johnson who helped bring ICOTYDE from discovery to patients.
Read more: tinyurl.com/TIMEbestinvent…
#TIMEBestInventions #ICOTYDE #PeptideInnovation
